PharmTech Talk - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Talk
INTERPHEX 2008 offered visitors novel experiences and many stimulating sessions.


Pharmaceutical Technology


Erik Greb
Various groups have questioned the efficacy and safety of generics lately. That this topic is now being widely debated serves as a reminder that a drug is more than an active pharmaceutical ingredient, or API.

A prominent generic currently at the center of controversy is Teva's "Budeprion XL 300" (bupropion HCl), a generic version of GlaxoSmithKline's "Wellbutrin XL 300" antidepressant. Some patients who switched from Wellbutrin XL 300 to Budeprion XL 300 reported having panic attacks, anxiety, nausea, depression, and suicidal tendencies.

The reports spurred the independent http://ConsumerLab.com/ to study Teva's drug. The study showed that after two hours, Budeprion released four times as much API as did Wellbutrin.

Although bupropion HCl is no longer patent-protected, the drug-delivery technology in Wellbutrin still is. This could explain the large disparity in dissolution between Teva's and GSK's products.

Drug companies, doctors, and patients mostly focus on APIs as the solutions to any disease. Though it's true the API is what relieves symptoms or cures a condition, it's not the end of the story.

We might think, as generics companies have argued, that generic treatments deserve less scrutiny because the drugs have already been tested and approved. But this argument does not take into account excipients, stability, formulation, or drug delivery mechanism. These elements influence a drug's safety and efficacy, and they could mean the difference between a beneficial treatment and a harmful substance.

Have a comment on this subject? Log onto Pharmaceutical Technology's new blog, http://blog.pharmtech.com/, and share your thoughts today.

Erik Greb is an assistant editor of Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here